Adeona Pharmaceuticals (AMEX: AEN) has received a $1 million equity investment from a Florida private equity firm as the drug developer looks to bring a drug to market for the first time. The funding comes from the sale of 1.2 million shares to Seaside 88 LP, according to a statement from Adeona. Any source of […]
The last couple years have been a bumpy ride for Adeona Pharmaceuticals. The company nearly collapsed in the wake of an FDA rejection of its top drug candidate, Coprexa, in January 2008, and Adeona has had four different chief executives in the last 12 months. Perhaps seeking a divorce from the bad memories, the company […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Adeona Pharmaceuticals has enrolled half of the patients it hopes to sign up for trials of its multiple sclerosis drug Trimesta. The company is in the midst of what it calls Phase "2/3" trials of Trimesta and has enrolled 75 of a planned 150 patients.
For the second time in less than a year, Adeona Pharmaceuticals has hired a new chief executive. Dr. James Kuo, who's served on the company's board since 2007, takes over as the company's CEO, president and chairman of the board.